for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc (ADR)

GSK

Latest Trade

41.77USD

Change

0.45(+1.09%)

Volume

2,296,224

Today's Range

41.38

 - 

41.85

52 Week Range

36.41

 - 

42.49

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
41.32
Open
41.73
Volume
2,296,224
3M AVG Volume
47.69
Today's High
41.85
Today's Low
41.38
52 Week High
42.49
52 Week Low
36.41
Shares Out (MIL)
4,988.15
Market Cap (MIL)
103,111.00
Forward P/E
13.94
Dividend (Yield %)
4.90

Next Event

GlaxoSmithKline PLC Vaccines Investor Event

Latest Developments

More

GSK Gets Positive CHMP Opinion For Intravenous Benlysta In Children With Lupus Aged 5 & Above

Microsoft - Charles Noski And Helmut Panke To Retire From Board - SEC Filing

FDA Panel Says Benefits Of GlaxoSmithKline's OTC Nicotine Oral Spray Outweigh Risks

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc (ADR)

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Major Drugs

Contact Info

G S K House, 980 Great West Road

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

37.7K

2017

38.9K

2018

41.1K

2019(E)

41.7K
EPS (USD)

2016

2.660

2017

2.910

2018

3.104

2019(E)

2.963
Price To Earnings (TTM)
18.05
Price To Sales (TTM)
2.59
Price To Book (MRQ)
22.77
Price To Cash Flow (TTM)
10.15
Total Debt To Equity (MRQ)
925.84
LT Debt To Equity (MRQ)
645.07
Return on Investment (TTM)
12.65
Return on Equity (TTM)
8.20

Latest News

Microsoft nominates GSK CEO Walmsley to board

Microsoft Corp said on Thursday it has nominated GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley to its board of directors.

GSK fights bid to strike new Zofran preemption evidence

A federal judge on Wednesday signaled he may strike some new evidence GlaxoSmithKline Plc put forward in its renewed bid to argue federal law preempts state law claims in a case that alleges the company failed to warn that its anti-nausea drug Zofran can cause birth defects.

GSK's over-the-counter nicotine oral spray gets FDA panel backing

An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their addiction.

FDA panel recommends GSK's over-the-counter nicotine oral spray

An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their nicotine addiction.

CORRECTED: GSK loses bid to overturn $89.7 mln verdict based on lawyer's statements at trial

A federal judge has rejected GlaxoSmithKline PLC's bid to overturn an $89.7 million verdict after a jury found its Ellipta inhaler infringed a patent belonging to rival drug company Vectura Ltd.

UPDATE 2-AstraZeneca respiratory business gets boost from 3-drug inhaler results

* Fasenra gets U.S. FDA orphan drug status (Adds details on Breztri data)

GSK builds oncology pipeline as drug shown to help myeloma patients

GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business.

GSK's long acting HIV injection gets boost from study

GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective...

GSK new HIV two-drug injection meets main goal in late-stage study

British drugmaker GlaxoSmithKline Plc said on Thursday its long-lasting two-drug regimen to treat HIV met the main goal of a late-stage study.

IN BRIEF: GSK to face first Zofran birth defects trial in January

A federal judge overseeing hundreds lawsuits by women who claim the anti-nausea drug Zofran causes birth defects and that GlaxoSmithKline PLC failed to warn of its risks on Wednesday said the first trial nationally would take place in January.

AstraZeneca scores win in race to treat ovarian cancer

AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

GSK ends development of Ebola vaccine, hands work to U.S. institute

British drugmaker GlaxoSmithKline <GSK.L> is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK hands work on potential Ebola vaccines to U.S. institute

British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK raises 2019 earnings expectations after standout quarter for Shingrix

GlaxoSmithKline <GSK.L> beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.

REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix

GlaxoSmithKline Plc on Wednesday forecast a smaller than previously estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

GSK forecasts smaller hit to FY profit after Q2 beat

GlaxoSmithKline Plc on Wednesday forecast a smaller-than estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

Drugmaker GSK ends chairman search with HSBC's Symonds

GlaxoSmithKline <GSK.L> has appointed HSBC's <HSBA.L> Jonathan Symonds to succeed Philip Hampton as non-executive chairman, ending a six month search as the drugmaker prepares to split its businesses into two.

GSK names HSBC's Symonds as non-exec chairman

Drugmaker GlaxoSmithKline Plc on Wednesday named HSBC's Jonathan Symonds as non-executive chairman to replace Philip Hampton. (Reporting by Pushkala Aripaka in Bengaluru; editing by Jason Neely)

Swiss agree to extradite Chinese scientist to U.S. on theft charges

Switzerland has agreed to extradite a Chinese researcher to the United States where prosecutors have charged him with helping his scientist sister steal secrets allegedly worth $550 million from British drugmaker GlaxoSmithKline.

GSK's two-drug HIV Dovato treatment meets main goal in study

(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up